Haematopoietic Growth Factors: Therapeutic Uses

Monika Engelhardt, University of Freiburg Medical Center, Freiburg, Germany
Yalin Guo, University of Freiburg Medical Center, Freiburg, Germany
Sebastian Fetscher, Städtisches Krankenhaus Süd, Lübeck, Germany
Roland Mertelsmann, University of Freiburg Medical Center, Freiburg, Germany

Published online: January 2006

DOI: 10.1038/npg.els.0004116

Haematopoietic growth factors (HGF) belong to the family of cytokines that are glycoprotein products of activated cells. Their main biological function is to influence the intercellular cell communication and thereby cell survival, self-renewal, proliferation, differentiation and activation at all levels of haematopoietic cell development. The clinical application of HGF was one of the main contributions in medicine and has increased the therapeutic options achieved during the last two decades of the twentieth century.

Keywords: growth factors; supportive care; G-CSF; erythropoietin; haematopoietic stem cell transplantation

 References
    Appelbaum FR (2004) Use of granulocyte colony-stimulating factor following hematopoietic cell transplantation: does haste make waste? Journal of Clinical Oncology 22: 390–391.
    Bennett CL, Luminari S, Nissenson AR et al. (2004) Pure red-cell aplasia and epoetin therapy. New England Journal of Medicine 351: 1403–1408.
    Doorduijn JK, van der Holt B, van Imhoff GW et al. (2003) CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 21: 3041–3050.
    Engelhardt M, Bertz H, Afting M et al. (1999) High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. Journal of Clinical Oncology 17: 2160–2172.
    Engelhardt M, Bertz H, Wasch R and Finke J (2001a) Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation. Annals of Hematology 80: 201–208.
    Engelhardt M, Ozkaynak MF, Drullinsky P et al. (1998) Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia 12: 13–24.
    Faderl S and Kantarjian HM (2004) Novel therapies for myelodysplastic syndromes. Cancer 101: 226–241.
    Heath JA, Steinherz PG, Altman A et al. (2003) Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a children's cancer group study. Journal of Clinical Oncology 21: 1612–1617.
    Ho VT, Mirza NQ, Junco Dd D et al. (2003) The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplantation 32: 771–775.
    Joshi SS, Lynch JC, Pavletic SZ et al. (2001) Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 98: 1963–1970.
    Kaushansky K (2003) Thrombopoietin: a tool for understanding thrombopoiesis. Journal of Thrombosis & Haemostasis 1: 1587–1592.
    Lehmann U, Brakensiek K and Kreipe H (2004) Role of epigenetic changes in hematological malignancies. Annals of Hematology 83: 137–152.
    Löwenberg B, van Putten W, Theobald M et al. (2003) Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine 349: 743–752.
    Ozer H, Armitage JO, Bennett CL et al. (2000) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology 18: 3558–3585.
    Relling MV, Boyett JM, Blanco JG et al. (2003) Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101: 3862–3867.
    Ringden O, Labopin M, Gorin NC et al. (2004) Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 22: 416–423.
    Rowe JM, Neuberg D, Friedenberg W et al. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103: 479–485.
    Spielberger R, Stiff P, Bensinger W et al. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine 351: 2590–2598.
    Vose JM, Crump M, Lazarus H et al. (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Journal of Clinical Oncology 21: 514–519.
    Weiss G and Goodnough LT (2005) Anemia of chronic disease. New England Journal of Medicine 352: 1011–1023.

Related Sub-Topics:

Cytokines | Diagnostics, Therapeutics and Methods | Tumour Immunology | Cell Biology of Cancer
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Haematopoietic Growth Factors: Therapeutic Uses
 
How to Cite close
Engelhardt, Monika, Guo, Yalin, Fetscher, Sebastian, and Mertelsmann, Roland(Jan 2006) Haematopoietic Growth Factors: Therapeutic Uses. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0004116]